Toucan Capital Fund II, L.P. is a $120 million venture capital fund (SBIC) focused on seed and early-stage life science and advanced technology investments. Toucan Capital Corp. launched its first fund in 1997 and began investing its current fund in August of 2001. Toucan invests nationwide and is one of the largest and most active venture capital funds in seed and early-stage life science. Toucan has also been an early investor in nanotechnology. Toucan is especially active in the mid-Atlantic region, one of the richest markets in the country for life science and certain advanced technologies, and a market that has generally been underserved by venture capital.

Toucan usually serves as the lead or co-lead investor and takes an active, hands-on role working closely with company management to help build its portfolio companies. For example, Toucan often assists its portfolio companies in building and strengthening their intellectual property base, formulating partnering and regulatory strategies, and ensuring that commercialization and payment/reimbursement issues are addressed from the earliest stages of the company's development.

Our investment professionals have extensive backgrounds in science, engineering, and finance and have significant operational and management experience at various technology-based companies prior to joining Toucan Capital. Our primary offices are located in Bethesda, MD, outside of Washington, DC, just a few blocks from the National Institutes of Health.